2,6-Disubstituted piperiddines as modulators
    13.
    发明申请
    2,6-Disubstituted piperiddines as modulators 失效
    2,6-二取代的哌啶作为调节剂

    公开(公告)号:US20070179158A1

    公开(公告)日:2007-08-02

    申请号:US10586765

    申请日:2005-01-14

    摘要: The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译: 本发明还涉及式(I)的化合物:其中R 1,R 2,R 3,R 4, R 5,R 6,R 7,R 8,R 9,R 9, R 10,R 16,R 17,R 18,R 19,R 16, R 20,R 21,R 22和R 22如本文所定义),其是趋化因子受体活性的调节剂,并且可用于 预防或治疗某些炎性和免疫调节性疾病和疾病,过敏性疾病,特应性病症,包括过敏性鼻炎,皮炎,结膜炎和哮喘,以及自身免疫病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。

    Process for the preparation of CCR-2 antagonists
    15.
    发明授权
    Process for the preparation of CCR-2 antagonists 有权
    制备CCR-2拮抗剂的方法

    公开(公告)号:US07361765B2

    公开(公告)日:2008-04-22

    申请号:US10577587

    申请日:2004-10-25

    IPC分类号: C07D471/02

    摘要: The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-1{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine

    摘要翻译: 本发明提供了制备((1R,3S)-3-异丙基-3 - {[3-(三氟甲基)-7,8-二氢-1,6-二氮杂萘-6(5H) ]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺及其琥珀酸盐。 本发明另外提供了制备中间体(3R)-3-甲氧基四氢-4H-吡喃-4-酮的有效合成方法; (1S,4S)-4-(2,5-二甲基-1H-吡咯-1-基)-1-异丙基环戊-2-烯-1-羧酸; 和3-(三氟甲基)-5,6,7,8-四氢-1,6-萘啶; 制备前体(3S,4S)-N - ((1S,4S)-4-异丙基-4 - {[3-(三氟甲基)-7,8-二氢-1,6-萘啶-2-基] (5H) - 基]羰基}环戊-2-烯-1-基)-3-甲氧基四氢-2H-吡喃-4-胺。 本发明另外存在((1R,3S)-3-异丙基-3-1 {[3-(三氟甲基)-7,8-二氢-1,6-二氮杂萘-6(5H))的琥珀酸盐的优异性质 ) - 基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺

    2,6-disubstituted piperiddines as modulators
    19.
    发明授权
    2,6-disubstituted piperiddines as modulators 失效
    2,6-二取代的哌啶作为调节剂

    公开(公告)号:US07410961B2

    公开(公告)日:2008-08-12

    申请号:US10586765

    申请日:2005-01-14

    摘要: The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译: 本发明还涉及式(I)的化合物:其中R 1,R 2,R 3,R 4, R 5,R 6,R 7,R 8,R 9,R 9, R 10,R 16,R 17,R 18,R 19,R 16, R 20,R 21,R 22和R 22如本文所定义),其是趋化因子受体活性的调节剂,并且可用于 预防或治疗某些炎性和免疫调节性疾病和疾病,过敏性疾病,特应性病症,包括过敏性鼻炎,皮炎,结膜炎和哮喘,以及自身免疫病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。